Virtu KCG Holdings
MRTX

Virtu KCG Holdings’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Virtu KCG Holdings’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$55K Sell
15,020
-5,286
-26% -$20.3K ﹤0.01% 2570
2017
Q1 		$106K Buy
+20,306
New +$111K ﹤0.01% 2666
2016
Q3 		– Sell
-18,690
Closed -$102K – 3564
2016
Q2 		$102K Buy
+18,690
New +$298K ﹤0.01% 2537

Other funds holding MRTX

AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Hillhouse Investment Management
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Virtu KCG Holdings's MRTX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 26% in Q2 2017, selling an estimated $20.3K and leaving 15,020 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #2570.

Virtu KCG Holdings first reported a position in MRTX in Q2 2016 and has held it in 3 quarters since. The position peaked at $106K in Q1 2017. 51 funds tracked by Wall St. Rank hold MRTX as of Q2 2017.

  • Virtu KCG Holdings held 15,020 shares of Mirati Therapeutics, Inc. Common Stock worth $55K as of Q2 2017.
  • Virtu KCG Holdings sold 5,286 Mirati Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $20.3K.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2570 holding.
  • Virtu KCG Holdings first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2016 and has held it in 3 quarters since.
  • Virtu KCG Holdings's Mirati Therapeutics, Inc. Common Stock position peaked at $106K in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.